ADVM (adverum.com) מכפיל P/E עתידי

לוגו גרפי של adverum.com (ADVM)

Adverum Biotechnologies gene vector production facilities are operating normally. Business prospects rely on regulatory approval of innovative retinal treatments. This chart provided by GURU.Markets shows the company's forward P/E ratio at 0.00, helping to identify entry points. High R&D expenditures and strict FDA oversight create insurmountable barriers for new entrants.

Adverum Biotechnologies - יחס מחיר לרווח חזוי ADVM (תקופה 04.07.2022 - 20.12.2025)

פילוחים אנליטיים ודוחות נתונים של חברת Adverum Biotechnologies (ADVM)

ניתוח מקיף של החברה:adverum.com
מוצר ממותג של Adverum

The high scalability of gene therapies for eye diseases from Adverum Biotechnologies (ADVM) allows the company to replicate costly treatments at low expense. Reflecting these prospects, the business's forward P/E ratio compares market capitalization with expected annual net income, helping investors determine the asset's degree of overvaluation and identify entry points in oversold zones.